Thursday, February 02, 2023 7:20:04 AM
https://www.daiwair.co.jp/td_download.cgi?c=2160&i=2522199
Both the conversion of the Series X preferred stock and the acquisition of a 65.18% interest in Continent will be subject to Catalyst stockholder approval, which will be sought in 2023. If the acquisition is approved by stockholders, Catalyst would issue at closing a total of up to 1,110,776,224 shares of common stock for a controlling interest in Continent, at which point Catalyst would expect to consolidate results of operations with Continent.
“The asset purchase of F351 and the subsequent business combination with Continent allows CBIO to both accelerate the return of cash to stockholders and provide additional value to our stockholders through equity ownership of Continent and a CVR for the monetization of our legacy assets,” said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. “The company is continuing its efforts to monetize the legacy assets, and we expect to distribute additional cash in 2023. We believe that this set of transactions creates an attractive fibrosis company with further upside for our stockholders. Continent is profitable with a robust fibrosis pipeline in various stages of development, including a Phase 3 study of F351 in HBV associated fibrosis and a Phase 2 study poised to initiate in NASH fibrosis.”
Recent CBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2024 10:19:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2024 08:51:43 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2024 12:49:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 12:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2024 12:46:38 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/19/2024 08:06:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/09/2024 08:31:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/08/2024 10:03:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/05/2024 09:40:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/04/2024 09:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/03/2024 08:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:01:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2024 09:35:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2024 10:42:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 09:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 01:55:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:31:12 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:27:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/21/2024 11:15:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2024 08:47:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/15/2024 09:29:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:16:03 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:11:14 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/19/2024 09:05:30 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:01:35 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM